Keros Therapeutics

Keros Therapeutics is a company based in Lexington, Massachusetts, whose mission is to deliver clinical benefit to patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta (TGF-β) family of proteins. It focuses on differentiated product candidates designed to alter TGF-β signaling, targeting pathways critical for the growth, repair and maintenance of blood cells and tissues including bone, skeletal muscle, adipose and heart tissue. Its pipeline includes KER-065, being developed for neuromuscular diseases, and elritercept, being developed to treat ineffective hematopoiesis in myelodysplastic syndromes and myelofibrosis.

Keros Therapeutics is a company based in Lexington, Massachusetts. Its mission is to deliver significant clinical benefit to patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta (TGF-β) family of proteins. The company focuses on developing differentiated product candidates designed to alter TGF-β signaling, targeting pathways critical for the growth, repair and maintenance of blood cells and tissues including bone, skeletal muscle, adipose and heart tissue. Its pipeline includes KER-065 for neuromuscular diseases and elritercept for ineffective hematopoiesis in myelodysplastic syndromes and myelofibrosis.

Developing and commercializing novel therapeutics with the ability to modulate TGF-β signaling and unlock potentially disease-modifying benefits for patients.

• KER-065

  Being developed for the treatment of neuromuscular diseases.

• Elritercept

  Being developed to treat ineffective hematopoiesis in both myelodysplastic syndromes and myelofibrosis.

• 2020-12-17

  Alon Lazarus to step down from Keros Therapeutics board[6]Alon Lazarus将辞去Keros Therapeutics董事职务biospace.com

  Reported: 2020-12-17

  Keros Therapeutics announced that Alon Lazarus would be stepping down as a director, concurrent with Mary Ann Gray joining the board.

• 2020-02-26

  Keros Therapeutics appoints Keith Regnante as CFO[7]Keros Therapeutics 任命 Keith Regnante 为首席财务官finanznachrichten.de

  Reported: 2020-02-26

  Keros Therapeutics announced the appointment of Keith Regnante as its Chief Financial Officer. He will lead financial and information technology operations and oversee investor relations and fundraising efforts.

1. 1Keros Therapeutics - Powered by TGF-ß science, inspired by patientskerostx.com
2. 2About Us - Keros Therapeuticskerostx.com
3. 3About Us - Keros Therapeuticskerostx.com
4. 4About Us - Keros Therapeuticskerostx.com
5. 5Keros Therapeutics (United States)wikidata.org
6. 6Alon Lazarus将辞去Keros Therapeutics董事职务biospace.com
7. 7Keros Therapeutics 任命 Keith Regnante 为首席财务官finanznachrichten.de